Key Publications.

Key Publications

  1. Recent publications
  2. Karin N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells and beyond. Front Immunol. 2020.
  3. Karin N, Razon H. The role of CCR5 in directing the mobilization and biological function of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells in cancer. Cancer Immunol Immunother. 2018 Sep 19. PubMed PMID: 30232521.
  4. Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018 Feb 12. PubMed PMID: 29449068.
  5. Karin N. Chemokines and cancer: new immune checkpoints for cancer therapy. Curr Opin Immunol. 2018 Mar 23;51:140-5. PubMed PMID: 29579623.
  6. Karin N. Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity. Front Immunol. 2018;9:623. PubMed PMID: 29651292. Pubmed Central PMCID: 5884937.
  7. Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V. CCR5(+) Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. Cancer Res. 2018 Jan 1;78(1):157-67. PubMed PMID: 29089297.(Equal contribution of both last authors)
  8. Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y, Umansky V, Karin N. CCR5 Directs the Mobilization of CD11b(+)Gr1(+)Ly6C(low) Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. Cell Rep. 2017 Nov 21;21(8):2212-22. PubMed PMID: 29166611.
  9. Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N. CCR8(+)FOXp3(+) Treg cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-91. PubMed PMID: 28533380. Pubmed Central PMCID: 5468670.

Key discoveries:

The discovery that chemokines also direct the linage development of T cells

  1. Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N. CCR8(+)FOXp3(+) Treg cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-91. PubMed PMID: 28533380. Pubmed Central PMCID: 5468670.
  2. Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, Barsheshet Y, Karp CL, Karin N. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest. 2014 May 1;124(5):2009-22. PubMed PMID: 24713654. Pubmed Central PMCID: 4001543.
  3. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008 Oct 27;205(11):2643-55. PubMed PMID: 18852294. Pubmed Central PMCID: 2571938.
  4. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002 Jun 1;168(11):5885-92. PubMed PMID: 12023393. Epub 2002/05/23. eng.
  5. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol. 2002 Sep 1;169(5):2685-93. PubMed PMID: 12193742.

The discovery of a novel regulatory mechanism in which autoantibodies to inflammatory cytokines and chemokines restrain autoimmunity

  1. Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity. 2003 Nov;19(5):679-88. PubMed PMID: 14614855.

 

The discovery of adhesion molecule that direct the migration of effector T cells to the inflamed central nervous system- A Nature paper that directly led to the development of the first FDA approved biological drug for Multiple Sclerosis (Tysabri)

  1. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 Mar 5;356(6364):63-6. PubMed PMID: 1538783.